Modern view of non-alcoholic fatty liver disease
PDF (Русский)
DOCX

Keywords

non-alcoholic fatty liver disease, etiopathogenesis, liver fibrosis, diagnostics, treatment

How to Cite

Tanryberdieva, T. O., Beknepesova, M. C., Gurbanov, V. A., & Agahanowa, O. N. (2016). Modern view of non-alcoholic fatty liver disease. Herald of Pancreatic Club, 31(2), 49-55. https://doi.org/10.33149/vkp.2016.02.08

Abstract views: 31
PDF Downloads: 15 PDF Downloads: 22

Abstract

Leading place among metabolic disorders, such as diabetes of the 2nd type, infringement of glucose tolerance, insulin-resistance, adiposity and/or modification of blood lipid spectrum resulting in heavy inflammation and destructive processes quite often up to development of hepatic cirrhosis, is taken by primary non-alcoholic fatty liver disease.

Timely diagnostics and detection of possible risk factors of adverse course of the disease are necessary in veiw of selection of rational methods of treatment preventing further progress of non-alcoholic fatty liver disease.

https://doi.org/10.33149/vkp.2016.02.08
PDF (Русский)
DOCX

References

1. A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease: Abstracts of The International Liver Congress 2013, Amsterdam, April 24–28, 2013 / Q. M. Anstee, R. Darlay, J. Leathart [et al.] // Hepatology. – 2013. – Vol. 58, No 1. – P. S46.
2. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease / G. Musso, R. Gambino, M. Cassader, G. Paganu // Hepatology. – 2010. – Vol. 52. – P. 79–104.
3. A position statement on NAFLD/NASH based on the EASL 2009 special conference / V. Ratziu, S. Bellentani, H. Cortez-Pinto [et al.] // Hepatology. –2010. – Vol. 53. – P. 372–384.
4. Anstee Q. M. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis / Q. M. Anstee, G. Targher, C. P. Day // Nat. Rev. Gastroenterol. Hepatol. – 2013. – Vol. 10. – P. 330–344.
5. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? / S. McPherson, Q. M. Anstee, E. Henderson [et al.] // Eur. J. Gastroenterol. Hepatol. – 2013. – Vol. 25. – P. 652–658.
6. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis and degree of hepatic fibrosis / J. W. Molloy [et al.] // Hepatology. – 2012. – Vol. 55. – P. 429.
7. Bruix J. American Association for the Study of Liver. Management of hepatocellular carcinoma : an update / J. Bruix, M. Sherman // Hepatology. – 2011. – Vol. 53. – P. 1020–1022.
8. Dyson J. K. Non-alcoholic fatty liver disease: a practical approach to treatment / J. K. Dyson, Q. M. Anstee, S. Mcpherson // Frontline Gastro. – 2014. – Vol. 5, No 4. – P. 225–226.
9. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial / J. E. Lavine, J. B. Schwimmer, M. L. Van Natta [et al.] // JAMA. – 2011. – Vol. 305. – P. 1659–1668.
10. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition / M. Charlton, A. Krishnan, K. Viker [et al.] // Am. J. Physiol. Gastrointest. Liver Physiol. – 2011. – Vol. 301. – P.825–834.
11. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat : The Framingham Heart Study / E. K. Speliotes, J. M. Massaro, U. Hoffmann [et al.] // Hepatology. – 2010. – Vol. 51. – P. 1979–1987.
12. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States / M. R. Charlton, J. M. Burns, R. A. Pedersen [et al.] // Gastroenterology. – 2011. – Vol. 141. – P. 1249–1253.
13. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease / S. Romeo, J. Kozlitina, C. Xing [et al.] // Nat. Genet. – 2008. – Vol. 40. – P. 1461–1465.
14. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits / E. K. Speliotes, L. M. Yerges-Armstrong, J. Wu [et al.] // PLoS Genet. – 2011. – Vol. 7, No 3. – P. e1001324.
15. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis / P. N. Newsome, M. E. Allison, P. A. Andrews [et al.] // Gut. – 2012. – Vol. 61. – P. 484–500.
16. Magnetic resonance elastography of liver : technique, analysis and clinical applications / S. K. Venkatesh [et al.] // Journal of Magnetic Resonance Imaging. – 2013. – Vol. 37. – P. 544.
17. Meta-analysis : pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis / E. Boettcher, G. Csako, F. Pucino [et al.] // Aliment. Pharmacol. Ther. – 2012. – Vol. 35. – P.66–75.
18. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies / H. P. Chen, J. J. Shieh, C. C. Chang [et al.] // Gut. – 2013. – Vol. 62. – P. 606–615.
19. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease / K. Yalamanchili, S. Saadeh, G. B. Klintmalm [et al.] // Liver Transpl. – 2010. – Vol. 16. – P. 431–439.
20. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors / G. Guaraldi, N. Squillace, C. Sentarelli [et al.] // Clin. Infect. Dis. – 2008. – Vol. 47. – P. 250–257.
21. Omega-3 supplementation and non-alcoholic fatty liver disease : a systematic review and meta-analysis / H. M. Parker, N. A. Johnson, C. A. Burdon [et al.] // Hepatology. – 2012. – Vol. 56. – P. 944–951.
22. Paschos P. Nonalcoholic fatty liver disease and the renin-angiotensin system: implications for treatment / P. Paschos, K. Tziomalos // World J. Hepatol. – 2012. – Vol. 4. – P. 327–331.
23. Peng L. Weight reduction for non-alcoholic fatty liver disease / L. Peng, J. Wang, F. Li // Cochrane Database Syst. Rev. – 2011. – Vol. 6. – P. 2–11.
24. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis / A. J. Sanyal, M. B. Chalasani, K. V. Kowdley [et al.] // N. Engl. J. Med. – 2010. – Vol. 362. – P. 1675–1685.
25. PNPLA3 variants specifically confer increased risk for histologic NAFLD but not metabolic disease / E. K. Speliotes, J. L. Butler, C. D. Palmer [et al.] // Hepatology. – 2010. – Vol. 52. – P. 904–912.
26. Practice guidelines for the diagnosis and management of nonalcoholic fatty disease / P. Loria, L. E. Adinolfi, S. Bellentani [et al.] // Dig. Liver Dis. – 2010. – Vol. 42. – P. 272–282.
27. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy : a prospective study / C. D. Williams, J. Stengel, M. I. Asike [et al.] // Gastroenterology. – 2011. – Vol.140. – P. 124–131.
28. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese : a population study using proton-magnetic resonance spectroscopy and transient elastography / V. W. Wong, W. C. Chu, G. L. Wong [et al.] // Gut. – 2012. – Vol. 61. – P. 409–415.
29. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis / K. Promrat, D. E. Kleiner, H. M. Niemeier [et al.] // Hepatology. – 2010. – Vol. 51. – P. 121–129.
30. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease / S. McPherson, S. F. Stewart, E. Henderson [et al.] // Gut. – 2010. – Vol. 59. – P. 1265–1269.
31. Statin use and the risk of liver cancer : a population-based case-control study / H. F. Chiu, S. C. Ho, C. C. Chen [et al.] // Am. J. Gastroenterol. – 2011. – Vol. 106. – P. 894–898.
32. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth / G. J. Van Der Heijden, Z. J. Wang, Z. Chu [et al.] // Med. Sci. Sport Exerc. – 2010. – Vol. 42. – P. 1973–1980.
33. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology / N. Chalasani, Z. Younossi, J. E. Lavine [et al.] // Gastroenterology. – 2012. – Vol. 142. – P. 1592–1609.
34. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis / M. S. Ascha, I. A. Hanouneh, R. Lopez [et al.] // Hepatology. – 2010. – Vol. 51. – P. 1972–1978.
35. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease / M. C. Ryan, C. Itsiopoulos, T. Thodis [et al.] // Hepatology. – 2013. – Vol. 59. – P. 138–143.
36. Thoma C. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults : a systematic review / C. Thoma, C. P. Day, M. I. Trenell // Hepatology. – 2012. – Vol. 56. – P. 255–266.